Oragenics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kim Murphy

Chief executive officer

US$341.1k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	12.8yrs

Recent management updates

Recent updates

CEO

Kim Murphy (58 yo)

less than a year

Tenure

US$341,050

Compensation

Ms. Kimberly M. Murphy, also known as Kim, served as an Independent Chairman of the Board at Clarus Therapeutics Holdings, Inc. since September 9, 2021 until October 31, 2022. She serves as Director at Ora...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kimberly Murphy	President	less than a year	US$341.05k	no data
Martin Handfield	Senior Vice President of Discovery Research	8.3yrs	US$550.79k	no data
Janet Huffman	CFO, Secretary & Treasurer	less than a year	no data	no data

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: UAV's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kimberly Murphy	President	2.9yrs	US$341.05k	no data
Frederick Telling	Independent Director	12.8yrs	US$438.66k	0.86% $ 49.9k
Alan Dunton	Independent Director	12yrs	US$331.63k	0.035% $ 2.0k
Charles Pope	Independent Chairman of the Board	12.8yrs	US$307.30k	0.024% $ 1.4k
Robert Koski	Independent Director	13.8yrs	US$274.80k	0.19% $ 11.3k
Timothy Cooke	Member of Scientific Advisor	no data	no data	no data
David Zarley	Member of Scientific Advisor	no data	no data	no data
Terrence Cochrane	Member of Scientific Advisor	no data	no data	no data

12.8yrs

Average Tenure

68yo

Average Age

Experienced Board: UAV's board of directors are seasoned and experienced ( 12.8 years average tenure).

Oragenics Management

Management criteria checks 2/4

Key information

Recent management updates

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Recent updates

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Executive Chairman recently bought €59k worth of stock

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

New 90-day high: €1.10

Oragenics, Inc. Provides Update on Competitive Positioning of Terra CoV-2 Vaccine Against SARS-CoV-2, Expects to File IND in Third Quarter of 2021

New 90-day high: €0.61

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Insider recently sold €1.7m worth of stock

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million.

New 90-day low: €0.38

New 90-day low: €0.44

Oragenics, Inc. Announces Receipt of Feedback to Its Type B Pre-Ind Meeting Request from the U.S. Food and Drug Administration

New 90-day low: €0.45

Oragenics, Inc. (AMEX:OGEN) acquired Noachis Terra Inc. from Joseph Hernandez for $6.6 million.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age